Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 13 of 13 publications.
Skip to main content
Bhattacharya R, Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Calhoun SR, Poulos C. Exploring perceptions of the risk of recurrence in renal cell carcinoma: evidence from a survey of practicing physicians. Poster presented at the 2023 American Urological Association Annual Meeting; April 28, 2023. Chicago, IL. [abstract] J Urol. 2023 Apr 1; 209(Supplement 4):e271. doi: 10.1097/JU.0000000000003244.15
Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU. Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study. J Urol. 2020 Aug;204(2):273-80. doi: 10.1097/JU.0000000000000754
Phiri K, Hallas J, Linder M, Margulia A, Suehs B, Arana A, Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946
Barnett C, Auffenberg G, Cheng Z, Yang F, Wang J, Wei J, Miller D, Montie J. Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk? Poster presented at the 112th American Urological Association Annual Meeting; May 2017. Boston, MA. [abstract] J Urol. 2017 Apr; 197(4 Supplement):e552-3. doi: 10.1016/j.juro.2017.02.1311
Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clin Pract. 2014 Dec;68(12):1503-7. doi: 10.1111/ijcp.12521
Martin SA, Coon CD, McLeod LD, Chandran A, Arnold LM. Evaluation of the fibromyalgia diagnostic screen in clinical practice. J Eval Clin Pract. 2014 Apr;20(2):158-65. doi: 10.1111/jep.12102
Brown TM, Garg S, Chandran AB, McNett M, Silverman SL, Hadker N. The impact of 'best-practice' patient care in fibromyalgia on practice economics. J Eval Clin Pract. 2012 Aug 1;18(4):793-8.
Rosen RC, Wincze J, Mollen MD, Gondek K, McLeod LD, Fisher WA. Responsiveness and minimum important differences for the erection quality scale. J Urol. 2007 Nov 1;178(5):2076-81.
Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.
Berger A, Dukes E, Martin SA, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with FMS. Int J Clin Pract. 2007 Sep 1;61(9):1498-508.
Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2004 Dec;172(6 Pt 1):2321-5. doi: 10.1097/01.ju.0000140957.31325.7f
Yang BK, Young MD, Calingaert B, Albala DM, Vieweg J, Murphy BC, Dahm P. Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol. 2004 Jul 1;172(1):264-8.